Mirvetuximab Soravtansine in Solid Tumors: A Systematic Review and Meta-Analysis
Author Information
Author(s): Rehim Shamsnur, Yuan Shuang, Wang Hongjing
Primary Institution: West China Second University Hospital, Sichuan University, Chengdu, China
Hypothesis
The efficacy and safety of Mirvetuximab Soravtansine (MIRV) in treating solid tumors need to be evaluated through a systematic review and meta-analysis.
Conclusion
MIRV has significant therapeutic effects in solid tumors, especially when combined with Bevacizumab, and is relatively safe with manageable adverse reactions.
Supporting Evidence
- The pooled median progression-free survival (mPFS) was 6.70 months.
- The objective response rate (ORR) was 36%.
- Combination therapy with MIRV and Bevacizumab showed improved efficacy compared to MIRV alone.
- Adverse effects were mostly mild and manageable.
- Significant heterogeneity was observed among the included studies.
Takeaway
This study looked at a new cancer treatment called MIRV and found it works well, especially when used with another drug called Bevacizumab, and it usually doesn't cause serious side effects.
Methodology
A systematic search was conducted to identify clinical trials of MIRV in solid tumors, analyzing median progression-free survival and objective response rates using a random-effects model.
Potential Biases
High risk of bias due to confounding factors in non-randomized studies.
Limitations
Many included studies were single-arm trials, which may introduce bias and limit the quality of evidence.
Participant Demographics
Participants primarily had gynecological cancers, many with prior treatments and confirmed platinum resistance.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 4.54–8.86 for mPFS; 95% CI 28% to 44% for ORR
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website